LevelJump Announces Management Change
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") wishes to announce the appointment of Gus Patel as the Company's interim Chief Financial Officer effective September 1, 2026, replacing Robert Landau. Gus Patel is a finance executive, tax practitioner and licensed public accountant with more than 15 years of experience across public companies, private enterprises and professiona
Healthcare and Hospitals, Health
2026-09-09 8:37 AM EDT | LevelJump Healthcare Corp.
QScreen AI Announces Closing of Final Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the final tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the final tranche of its previously announced non-
2026-09-09 6:15 AM EDT | QScreen AI Inc.
WELL Health Announces Planned CFO Transition; Evelyn Sutherland Appointed Chief Financial Officer
WELL has appointed Evelyn Sutherland as Chief Financial Officer, effective September 21, 2026. Ms. Sutherland brings more than 20 years of senior financial leadership experience, including CFO roles at Staples Canada, Enercare Inc., KEYreit, and United Purchasing Group of Canada (Yum! Brands). Ms. Sutherland has served on the Board of WELL's subsidiary, WELLSTAR, over the past year and brings direct knowledge of the Company's strategy, governance an
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-09 6:00 AM EDT | WELL Health Technologies Corp.
Naia Relief Announces Closing of Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - Naia Relief Inc. (formerly, 1329308 B.C. Ltd.) (the "Company") announces that, further to its press releases dated October 3, 2025, July 6, 2026, July 30, 2026, August 19, 2026 and September 1, 2026, it has completed its previously announced reverse takeover transaction (the "Transaction") pursuant to which the Company acquired all of the issued and outstanding securities of Relief AI Inc. ("Relief AI").
2026-09-08 5:40 PM EDT | Naia Relief Inc.
Nasdaq Shareholder Requirements Just Verified By Adia Med
Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes: At least 300 round-lot holders; A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and Adia Med has just verified that it currently has 361 round-lot holders, or
Healthcare and Hospitals, Health
2026-09-08 8:00 AM EDT | Adia Med Inc.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder
Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future Fund The study is the first trial of PEX010 in a movement disorder and, to the Company's kno
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-08 7:52 AM EDT | Rhelion Life Sciences Corp.
Altrova Health Signs Exclusive U.S. Distribution Agreement to Launch Its Detection and Wellness Portfolio Across the United States
Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce that it has entered into an exclusive distribution agreement (the "Distribution Agreement") with Reliability Funding LLC ("Reliability" or the "Distributor") appointing Reliability as the Company's exclusive sales agent and distributor for its product portfolio across the entire United S
2026-09-08 7:07 AM EDT | Altrova Health Inc.
WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents
WELLTRUST™, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. HEALWELL's DARWEN™ AI platform is used to connect WELLTRUST™ patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Orga
Technology, Computer Software, Healthcare and Hospitals, Health
2026-09-08 6:30 AM EDT | WELL Health Technologies Corp.
Custom Health Completes Acquisition of Spencer Health Solutions, Bringing In-Home Medication Dispensing Technology Fully In-House
Effective September 4, 2026, Custom Health has completed its previously announced acquisition of Spencer Health Solutions, developer of the spencer® smart medication dispenser and in-home monitoring platform, giving the Company full ownership of the spencer® technology, intellectual property, and product roadmap. Spencer now operates as a wholly owned subsidiary of Custom Health, eliminating third-party support, infrastructure, and device costs previously incu
Technology, Pharmaceuticals, Health
2026-09-08 6:00 AM EDT | Custom Health Holdings Inc.
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company'
Biotechnology, Pharmaceuticals, Health
2026-09-08 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 202
Biotechnology, Pharmaceuticals, Health
2026-09-04 6:00 PM EDT | Defence Therapeutics Inc.
First Towers & Fiber Corp. Delivers First Cash Flow from New 200 KM Fiber Network, Eyes Expansion with Client
Toronto, Ontario--(Newsfile Corp. - September 4, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, today announced a series of operational and financial milestones that mark a significant step forward in the Company's transition into a recurring revenue-generating telecommunications infrastructure business. First Cash Lease Payment Col
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2026-09-04 9:05 AM EDT | Akanda Corp
Edison Issues Report on Percheron Therapeutics (PER)
London, United Kingdom--(Newsfile Corp. - September 4, 2026) - Edison issues report on Percheron Therapeutics (ASX: PER) Percheron's clinical strategy has taken an important turn with the announcement of an investigator-sponsored exploratory study of HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), led by Vanderbilt Health. Percheron's contribution will be limited to providing the study drug, a financial grant and advisory support. Following the announcement
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-09-04 5:00 AM EDT | Edison Group
Tersis Technologies Engages DIFFRNT Developments to Lead Web Development and Digital Infrastructure
Miami, Florida--(Newsfile Corp. - September 3, 2026) - Tersis Technologies, Inc. (OTCID: TERS), a clean technology company advancing waste-to-value and circular infrastructure solutions, today announced that it has engaged DIFFRNT Developments to lead the development, hosting, and ongoing management of the Company's web platforms and digital infrastructure. The engagement brings Tersis's website development, hosting, maintenance, cybersecurity, technical search optimization, CRM integra
Agriculture, Energy, Alternative Energy, Health
2026-09-03 1:01 PM EDT | Tersis Technologies Inc.
AVANT and Health In A Box Launch Physician-Led Preventive Health Programs For Club Members
Toronto, Ontario--(Newsfile Corp. - September 3, 2026) - AVANT, the premium private fitness and wellness club, and Health In A Box® today announced a partnership that brings physician-led preventive health programs to AVANT members beginning in mid-September. Members receive biomarker testing, clinical interpretation, and a personalized health action plan built with a clinical team of physicians and naturopathic doctors. Clinical review and follow-up are delivered virtually. AVANT'
Healthcare and Hospitals, Health
2026-09-03 8:00 AM EDT | Health In A Box Inc.
Rhelion Life Sciences Confirms Further Delivery of Filament Health's PEX010 to Germany's First Psilocybin Compassionate Use Program
Filament Health has completed a further international delivery of its patented, naturally derived psilocybin drug candidate PEX010 to Germany, supporting the first compassionate use program for psilocybin in the European Union The Company believes the continued delivery demonstrates Filament's ability to manufacture, release and supply pharmaceutical-grade botanical psilocybin across international regulatory jurisdictions as new legal access pathways emerge
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-09-03 7:39 AM EDT | Rhelion Life Sciences Corp.
DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of innovative point-of-care eye diagnostic solutions, is pleased to announce the submission of a pre-submission request to the U.S. Food and Drug Administration ("FDA") for its TeaRx™ Red Eye diagnostic test (the "Pre-Submission"). The Pre-Submission represents an important regulatory miles
2026-09-03 7:00 AM EDT | DiagnosTear Technologies Inc.
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026. Dr Zak
Biotechnology, Pharmaceuticals, Health
2026-09-03 7:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. All financial figures are expressed in Canadian dollars ($) unless otherwise noted, are prepared in accordance with International Financial Reporting Standards (IFRS), and are unaudited. In the second quarter o
2026-09-03 6:00 AM EDT | Restart Life Sciences Corp.
Charlotte's Web Applauds Congressional Action to Advance Continuing Resolution
Louisville, Colorado--(Newsfile Corp. - September 2, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF), the market leader in hemp extract wellness products, today welcomed the U.S. House of Representatives' passage of the continuing resolution (CR), which was approved by a vote of 370-48, following the Senate's earlier passage of the measure. The legislation will now be sent to the President for signature and enactment into law. The passage of the CR helps ensure
2026-09-02 11:07 AM EDT | Charlotte's Web Holdings, Inc.